Eikon Therapeutics, Inc. (EIKN)
| Market Cap | 445.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -333.64M |
| Shares Out | 54.14M |
| EPS (ttm) | -115.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 165,347 |
| Open | 8.77 |
| Previous Close | 8.74 |
| Day's Range | 7.90 - 9.10 |
| 52-Week Range | 7.90 - 17.40 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 25.60 (+210.83%) |
| Earnings Date | Mar 30, 2026 |
About EIKN
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-pen... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for EIKN stock is "Buy." The 12-month stock price target is $25.6, which is an increase of 210.83% from the latest price.
News
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non...
Eikon Therapeutics valued at $860 million in Nasdaq debut
Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq debut on Thursday, valuing the company at about $860.3 million.
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
Drug developer Eikon Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece.
Eikon Therapeutics targets $908 million valuation in US IPO
Drug developer Eikon Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.
Biopharmaceutical firm Eikon Therapeutics files for US IPO
Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.
Eikon Therapeutics IPO Registration Document (S-1)
Eikon Therapeutics has filed to go public with an IPO on the NASDAQ
Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, the deal size...